Amarin Corp Plc (AMRN)

[sts66]

If I recall correctly STRENGTH duration was expected to be 3.5 years but they may be running a bit long, so let’s call it 3.7 years.

Actually, the trial was extended by a full year, pushed out from H2/19 to H2/20 - how does that affect your numbers?

Some of us have asked a question that has gone unanswered - how did the trial get an extra year added when it's an event driven trial? Is event rate slower than expected or are they going over the planned # of events, and if the latter is true, is it ethical? If it's the former, given that these are higher risk patients than R-IT recruited, does that point to E having better efficacy than what people expect?

Even if they have good or great numbers, for now AMRN IP has blocked them from marketing E in the US - wonder how good results have to be for AZN to pull out all the stops and go full bore in court trying to overturn the IP protection?